Takeda’s oveporexton among key value-driving biopharma catalysts in Q3 2026, reveals GlobalData
Regulatory catalysts are set to shape biopharma sentiment in Q3 2026, with a selective pipeline of approval decisions and clinical milestones highlighting where ...



















